Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?
Open Access
- 24 May 2005
- journal article
- review article
- Published by CMA Impact Inc. in CMAJ : Canadian Medical Association Journal
- Vol. 172 (11) , 1457-1459
- https://doi.org/10.1503/cmaj.1041100
Abstract
Last summer, the US Food and Drug Administration instructed manufacturers of antidepressants to issue warnings about perinatal complications associated with their products.[1][1] Physicians were advised to taper the dosage of antidepressants in pregnant women during the last trimester so that theKeywords
This publication has 17 references indexed in Scilit:
- Neonate Characteristics After Maternal Use of Antidepressants in Late PregnancyArchives of Pediatrics & Adolescent Medicine, 2004
- Pharmacologic Factors Associated With Transient Neonatal Symptoms Following Prenatal Psychotropic Medication ExposureThe Journal of Clinical Psychiatry, 2004
- Risks of untreated depression during pregnancy.2004
- [Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy].2003
- Effects of Exposure to Selective Serotonin Reuptake Inhibitors During Pregnancy on Serotonergic Symptoms in Newborns and Cord Blood Monoamine and Prolactin ConcentrationsArchives of General Psychiatry, 2003
- Birth outcomes after prenatal exposure to antidepressant medicationAmerican Journal of Obstetrics and Gynecology, 2003
- Perinatal Outcome Following Third Trimester Exposure to ParoxetineArchives of Pediatrics & Adolescent Medicine, 2002
- Revision of the Postpartum Depression Predictors InventoryJournal of Obstetric, Gynecologic & Neonatal Nursing, 2002
- Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling.2001
- Paroxetine levels in postpartum depressed women, breast milk, and infant serum.The Journal of Clinical Psychiatry, 2000